Old Web
English
Sign In
Acemap
>
authorDetail
>
Judy Doto
Judy Doto
Bevirimat
Pharmacokinetics
Medicine
Pharmacology
Virology
5
Papers
273
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
An Oral Human Drug Absorption Study to Assess the Impact of Site of Delivery on the Bioavailability of Bevirimat
2009
The Journal of Clinical Pharmacology
Alyson Connor
Phil Evans
Judy Doto
Corey Ellis
David E. Martin
Show All
Source
Cite
Save
Citations (18)
Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: An open-label, parallel-group study
2008
Clinical Therapeutics
David E. Martin
Hal Galbraith
Jared Schettler
Corey Ellis
Judy Doto
Show All
Source
Cite
Save
Citations (3)
Multiple-Dose Pharmacokinetics and Safety of Bevirimat, a Novel Inhibitor of HIV Maturation, in Healthy Volunteers
2007
Clinical Pharmacokinectics
David E. Martin
Robert A. Blum
Judy Doto
Hal Galbraith
Charles H. Ballow
Show All
Source
Cite
Save
Citations (42)
Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection
2007
Antimicrobial Agents and Chemotherapy
Patrick F. Smith
Abayomi B. Ogundele
Alan Forrest
John H. Wilton
Karl Salzwedel
Judy Doto
Graham P. Allaway
David E. Martin
Show All
Source
Cite
Save
Citations (151)
Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers
2007
Antimicrobial Agents and Chemotherapy
David E. Martin
Robert A. Blum
John H. Wilton
Judy Doto
Hal Galbraith
Gina L. Burgess
Philip C. Smith
Charles H. Ballow
Show All
Source
Cite
Save
Citations (59)
1